diagnosis and treatment of hepatocellular carcinoma from a new perspective of mirnas

Clicks: 169
ID: 172526
2015
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #55 of 78 articles by views in lontar komputer

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
The hepatocellular carcinoma (HCC) diagnosed by serum biomarkers is usually at late stages, and the five-year survival rate of HCC is extremely low. Therefore, it is necessary to develop an efficient and noninvasive biomarker that can detect HCC at an early stage and to explore a new strategy for the treatment of HCC. Abundant evidence has shown that microRNAs(miRNA)s is involved in the development and progression of HCC, and it can be a sensitive biomarker for the detection of HCC and a new target for the treatment of HCC. The article introduces the application of miRNAs in the diagnosis and treatment of HCC, and believes that the diagnosis and treatment strategy for HCC based on miRNAs has great potential in clinical application, yet remains to be studied.
Reference Key
qiang2015linchuangdiagnosis Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors ;LI Qiang
Journal lontar komputer
Year 2015
DOI
10.3969/j.issn.1001-5256.2015.06.037
URL
http://www.lcgdbzz.org/qk_content.asp?id=6576&ClassID=58144121
Keywords
carcinoma Gastroenterology

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.